ANDREW KIPKORIR BOIYWO CRNP
Prescription History 1093298739
Nurse Practitioner in Williamsport, PA


Quality Rating: 81.54 out of 100 score

NPI Status: Active since September 10, 2018

Contact Information

1705 WARREN AVE STE 206
SUITE 206
WILLIAMSPORT, PA
ZIP 17701
Phone: (570) 326-8090

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ANDREW KIPKORIR BOIYWO CRNP, an active Nurse Practitioner specialist practicing in Williamsport, PA. Our medical registry currently tracks 11 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 612 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamsulosin Hcl, which accounts for 150 claims alone.


Alfuzosin Hcl Er

Generic Formulation: Alfuzosin HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 120
30-Day Fills 223.5
Days Supply 6,705
PA State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills92.4
Peer Average Days Supply2,745
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 179.1% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,202.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.36

State Avg Cost Per Claim

$31.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Alfuzosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Alfuzosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Allopurinol

Generic Formulation: AllopurinolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 46.1
Days Supply 1,384
PA State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills112.3
Peer Average Days Supply3,296
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.0% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $145.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.07

State Avg Cost Per Claim

$14.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Therapeutic Applications

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems.

Dutasteride

Generic Formulation: DutasterideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 17
30-Day Fills 35.0
Days Supply 1,050
PA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills73.2
Peer Average Days Supply2,170
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,142.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$67.22

State Avg Cost Per Claim

$49.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.

Therapeutic Applications

This medication is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It works by reducing the size of the enlarged prostate. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate frequently or urgently (including during the middle of the night). It may also reduce the need for surgery to treat BPH. Dutasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. This medication should not be used by women or children.

Finasteride

Generic Formulation: FinasterideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 100
30-Day Fills 241.5
Days Supply 7,245
PA State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills128.1
Peer Average Days Supply3,757
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 72.4% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,226.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.26

State Avg Cost Per Claim

$16.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.

Therapeutic Applications

Finasteride is used to shrink an enlarged prostate (benign prostatic hyperplasia or BPH) in adult men. It may be used alone or taken in combination with other medications to reduce symptoms of BPH and may also reduce the need for surgery. Finasteride may improve symptoms of BPH and provide benefits such as decreased urge to urinate, better urine flow with less straining, less of a feeling that the bladder is not completely emptied, and decreased nighttime urination. This medication works by decreasing the amount of a natural body hormone (DHT) that causes growth of the prostate. Finasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. Women and children should not use this medication.

Methenamine Hippurate

Generic Formulation: Methenamine HippurateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 51
30-Day Fills 69.0
Days Supply 2,070
PA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills50.7
Peer Average Days Supply1,399
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 37.8% more claims than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,263.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.38

State Avg Cost Per Claim

$90.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Methenamine is used to prevent or control returning urinary tract infections caused by certain bacteria. It is not used to treat an active infection. Antibiotics must be used first to treat and cure the infection. Methenamine is a drug that stops the growth of bacteria in urine. This medication also contains an ingredient that helps to make the urine acidic. When the urine is acidic, methenamine turns into formaldehyde to kill the bacteria. This drug is effective only against bacterial infections in the urinary tract. It will not work for other types of bacterial infections (such as in the blood) or for viral infections (such as the common cold or flu). Unnecessary use or misuse of any antibacterial drug can lead to its decreased effectiveness.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 48
30-Day Fills 68.0
Days Supply 2,040
PA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills66.7
Peer Average Days Supply1,827
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,195.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$629.07

State Avg Cost Per Claim

$554.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Nitrofurantoin

Generic Formulation: Nitrofurantoin MacrocrystalSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 25
30-Day Fills 31.0
Days Supply 882
PA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills32.2
Peer Average Days Supply781
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $610.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.40

State Avg Cost Per Claim

$38.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.

Therapeutic Applications

Nitrofurantoin is an antibiotic used to treat or prevent certain bladder infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. This medication should not be used in infants younger than 1 month old (see also Precautions section). This drug should not be used to treat infections outside the bladder (including kidney infections such as pyelonephritis or perinephric abscesses).

Oxybutynin Chloride

Generic Formulation: Oxybutynin ChlorideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 21
30-Day Fills 39.0
Days Supply 1,170
PA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills41.0
Peer Average Days Supply1,138
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $532.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.35

State Avg Cost Per Claim

$20.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics. This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).

Potassium Citrate Er

Generic Formulation: Potassium CitrateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 35
30-Day Fills 57.0
Days Supply 1,710
PA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills49.3
Peer Average Days Supply1,456
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 34.6% more claims than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,378.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$125.10

State Avg Cost Per Claim

$150.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A powder that dissolves in water, which is administered orally, and is used as a diuretic, expectorant, systemic alkalizer, and electrolyte replenisher.

Therapeutic Applications

This medication is used to make the urine less acidic. This effect helps the kidneys get rid of uric acid, thereby helping to prevent gout and kidney stones. This medication can also prevent and treat certain metabolic problems (acidosis) caused by kidney disease. Citric acid and citrate salts (which contain potassium and sodium) belong to a class of drugs known as urinary alkalinizers. If you have a condition that requires you to limit your intake of potassium and sodium, your doctor may direct you to take a product that is lower in potassium and sodium.

Solifenacin Succinate

Generic Formulation: Solifenacin SuccinateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 29
30-Day Fills 47.0
Days Supply 1,410
PA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills49.5
Peer Average Days Supply1,439
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,288.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$78.92

State Avg Cost Per Claim

$72.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.

Therapeutic Applications

Solifenacin is used to treat an overactive bladder. By relaxing the muscles in the bladder, solifenacin improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. This medication belongs to the class of drugs known as antispasmodics.

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 150
30-Day Fills 275.0
Days Supply 8,210
PA State Average Benchmarks
Peer Average Claims92.0
Peer Average 30-Day Fills185.5
Peer Average Days Supply5,393
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 63.0% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,125.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.17

State Avg Cost Per Claim

$19.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ANDREW KIPKORIR BOIYWO CRNP provides transparency into local medical care patterns within Williamsport, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nurse Practitioner** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.